Virus purification and formulation process
Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
1. A process for making a virus product comprising:
a. obtaining a composition suitable for purification from a virus-infected host cell culture;
b. clarifying the composition obtained in step “a” by removing cells and cell debris from said composition by depth filtration;
c. subjecting the filtrate in step “b” to endonuclease digestion and 0.2 micron filtration sufficient to fragment host cell DNA followed by filtration;
d. purifying the filtrate obtained in step “c” via a cross-linked agarose matrix with a dextran sulfate functional group chromatography resin and a cross-linked agarose matrix with an octylamine ligand chromatography resin having a shell that excludes molecules with a molecular mass greater than approximately 700 kDa from passing through pores of the shell;
e. stabilizing and inactivating the product obtained in step “d” with an inactivating amount of β-PL;
f. after inactivating the product in step “e,” adjusting the temperature of the product from a lower temperature to about 25-30° C.;
g. filtering the product obtained in step “f”; and,
h. formulating the product obtained in step “g” bound to alum.
2. The process of claim 1 wherein the product obtained in step “h” contains less than about 45,000 ng of host cell protein per 0.5 mL of suspension.
3. The process of claim 1 wherein the infecting virus of the virus-infected host cell culture is at least one selected from the group of: Yellow Fever, Japanese Encephalitis, Dengue, and West Nile.
4. The process of claim 1 wherein the infecting virus is one capable of infecting a selected host cell type.
5. The process of claim 1 wherein the host cells are vero cells.
6. The process of claim 1 wherein the product obtained in step “h” contains no residual sucrose.
7. A process for making a virus product-comprising:
a. obtaining a composition suitable for purification from a virus-infected host cell culture;
b. clarifying the composition obtained in step “a” by depth filtration followed by flushing first with purified water and then with buffer;
c. subjecting the filtrate in step “b” to endonuclease digestion and 0.2 micron filtration sufficient to fragment host cell DNA followed by filtration;
d. purifying the filtrate obtained in step “c” via a cross-linked agarose matrix with a dextran sulfate functional group chromatography resin and a cross-linked agarose matrix with an octylamine ligand chromatography resin having a shell that excludes molecules with a molecular mass greater than approximately 700 kDa from passing through pores of the shell;
e. stabilizing and inactivating the product obtained in step “d” with an inactivating amount of β-PL;
f. after step “e” is completed, adjusting the temperature of the product from a lower temperature to about 25-30° C.;
g. filtering the product obtained in step “f”; and
h. formulating the product obtained in step “g” bound to alum;
wherein said product has no residual sucrose; and,
wherein said product has less than about 45,000 ng of host cell protein per 0.5 mL of suspension.
8. A process for making a drug product comprising:
a. obtaining a composition suitable for purification from a virus-infected host cell culture;
b. clarifying the composition obtained in step “a” by removing cells and cell debris from said composition by depth filtration;
c. subjecting the filtrate in step “b” to endonuclease digestion and 0.2 micron filtration sufficient to fragment host cell DNA followed by filtration;
d. purifying the filtrate obtained in step “c” via a cross-linked agarose matrix with a dextran sulfate functional group chromatography resin and a cross-linked agarose matrix with an octylamine ligand chromatography resin having a shell that excludes molecules with a molecular mass greater than approximately 700 kDa from passing through pores of the shell;
e. stabilizing and inactivating the viral product obtained in step “d” with an inactivating amount of β-PL;
f. after inactivating the viral product in step “e,” adjusting the temperature of the viral product from a lower temperature to about 25-30° C.;
g. filtering the product obtained in step “f”;
h. formulating the product obtained in step “g” bound to alum; and,
i. aseptically buffer exchanging the product in step h at least once.